Patel Naimish 4
4 · CRISPR Therapeutics AG · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
CRISPR (CRSP) CMO Naimish Patel Sells 3,786 Shares
What Happened
Naimish Patel, Chief Medical Officer of CRISPR Therapeutics (CRSP), had 10,000 restricted stock units (RSUs) convert into common shares on May 28, 2026. Following the vesting/conversion, 3,786 of those shares were sold in an open-market transaction on May 29, 2026 at $55.62 per share, generating $210,577. The sale was executed to satisfy tax withholding obligations under the company’s RSU settlement policy, not as a discretionary trade.
Key Details
- Transaction dates and prices:
- 2026-05-28: RSU conversion/exercise of derivative for 10,000 shares (acquired; price N/A).
- 2026-05-29: Open-market sale of 3,786 shares @ $55.62 = $210,577.
- Shares owned after transaction: not specified in the Form 4 filing.
- Footnotes:
- F1: Each RSU equals a right to one share of CRSP common stock.
- F2: The 3,786-share sale was required to cover tax withholding per the company RSU Settlement Policy (not discretionary).
- F3: The RSU award was granted May 28, 2024 for 40,000 shares with quarterly vesting through May 28, 2028.
- Filing timeliness: Form 4 was filed on 2026-06-01 for a May 28 transaction; this appears to be timely (filed within the standard two business days).
Context
This was a routine post-vesting transaction: RSUs vested and converted to shares, and a portion was sold immediately to meet tax-withholding requirements (a common, non-discretionary practice). Such mandated sales are generally not considered a strong signal about an insider’s view of the company’s prospects.
Insider Transaction Report
- Exercise/Conversion
Common Shares
[F1]2026-05-28+10,000→ 23,143 total - Sale
Common Shares
[F2]2026-05-29$55.62/sh−3,786$210,577→ 19,357 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-05-28−10,000→ 20,000 total→ Common Shares (10,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F3]This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028.